We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility and we would like to inform that the US FDA has issued an EIR against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that the inspection is closed.

October 14, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Exchange Plaza, Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Ref: Our letter dated August 14, 2026 on United States Food and Drug Administration (“US FDA”) inspection at our Unit 3 manufacturing facility, located at Gaddapotharam village, Jinnaram, Sangareddy District Dear Sir/Madam, Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 We refer to our letter dated August 14, 2026 regarding the US FDA inspection conducted at our Unit 3 manufacturing facility, located at Gaddapotharam Village, Jinnaram, Sangareddy District, and would like to inform that the US FDA has issued an Establishment Inspection Report (EIR) against the inspection conducted from August 10, 2026 to August 14, 2026. The US FDA has concluded that this inspection is "closed". This is for your information and records. Thanking you Yours Sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary